[go: up one dir, main page]

ES2145742T3 - Uso de una proteasa de herpes. - Google Patents

Uso de una proteasa de herpes.

Info

Publication number
ES2145742T3
ES2145742T3 ES92108420T ES92108420T ES2145742T3 ES 2145742 T3 ES2145742 T3 ES 2145742T3 ES 92108420 T ES92108420 T ES 92108420T ES 92108420 T ES92108420 T ES 92108420T ES 2145742 T3 ES2145742 T3 ES 2145742T3
Authority
ES
Spain
Prior art keywords
protease
herpes
protein
methods
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92108420T
Other languages
English (en)
Inventor
Bernard Roizman
Fenyong Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Development Corp
Original Assignee
Arch Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/832,855 external-priority patent/US5478727A/en
Application filed by Arch Development Corp filed Critical Arch Development Corp
Application granted granted Critical
Publication of ES2145742T3 publication Critical patent/ES2145742T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A LA IDENTIFICACION Y PURIFICACION DE UNA PROTEASA DE HERPES Y UNA CODIFICACION DE UN SEGMENTO DE ACIDO NUCLEICO PARA DOS PROTEINAS. LA PRIMERA PROTEINA ES LA PROTEASA DE HERPES QUE PUEDE DIVIDIRSE A SI MISMA Y TAMBIEN DIVIDIR LA SEGUNDA PROTEINA. ESTA PROTEASA SE REQUIERE PARA LA UNION DEL CAPSIDE DEL VIRUS DEL HERPES, POR ELLO ES ESENCIAL PARA DUPLICACION. LA SEGUNDA PROTEINA HA SIDO PREVIAMENTE DESIGNADA COMO DE LA FAMILIA DE PROTEINAS EN CELULAS VIRICAS INFECTADAS, ICP35. LA PROTEASA Y SUS SUBSTRATOS SE CODIFICAN MEDIANTE EL SOLAPADO DE LOS SEGMENTOS DE ACIDO NUCLEICO. ESTA INVENCION TAMBIEN SE REFIERE A UNA SECUENCIA PROMOTORA DE LA SEGUNDA PROTEINA. SE PRESENTAN METODOS PARA PRODUCIR UNA PROTEASA VIRICA, DEPURACION DE UN INHIBIDOR DE PROTEASA QUE PUEDE UTILIZARSE EN UN FARMACO DISEÑADO PARA EL TRATAMIENTO DE LA ENFERMEDAD DEL HERPES, METODOS PARA EL TRATAMIENTO DE HERPES Y OTRAS INFECCIONES VIRICAS EN DONDE EL VIRUS EMPLEA UNA PROTEASA SUBSTANCIALMENTESIMILAR A LA PROTEASA DEL HERPES, PARA PRODUCCION DE CAPSIDE. TAMBIEN SE INVENTAN METODOS PARA LA DETECCION DE INFECCIONES POR HERPES Y OTRAS INFECCIONES VIRICAS.
ES92108420T 1991-05-24 1992-05-19 Uso de una proteasa de herpes. Expired - Lifetime ES2145742T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70581491A 1991-05-24 1991-05-24
US07/832,855 US5478727A (en) 1991-05-24 1992-02-07 Methods and compositions for the preparation and use of a herpes protease

Publications (1)

Publication Number Publication Date
ES2145742T3 true ES2145742T3 (es) 2000-07-16

Family

ID=27107575

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92108420T Expired - Lifetime ES2145742T3 (es) 1991-05-24 1992-05-19 Uso de una proteasa de herpes.

Country Status (13)

Country Link
EP (1) EP0514830B1 (es)
JP (1) JP3355202B2 (es)
AT (1) ATE192494T1 (es)
AU (1) AU666305B2 (es)
CA (1) CA2069460C (es)
DE (2) DE69230984T4 (es)
ES (1) ES2145742T3 (es)
FI (1) FI104427B (es)
HU (1) HU216622B (es)
IE (1) IE921656A1 (es)
IL (1) IL101975A (es)
NO (1) NO303645B1 (es)
NZ (1) NZ242739A (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434074A (en) * 1991-07-05 1995-07-18 Gibson; D. Wade Cytomegalovirus proteinase
US6406902B1 (en) 1991-07-05 2002-06-18 Johns Hopkins University Herpes virus proteinase and methods of assaying
US5376633A (en) * 1992-09-30 1994-12-27 Lezdey; John Method for deactivating viruses in blood component containers
EP0708833A1 (en) * 1993-06-08 1996-05-01 Abbott Laboratories Herpes simplex virus type-2 protease
CN1133594A (zh) * 1993-08-20 1996-10-16 史密丝克莱恩比彻姆公司 单纯性疱疹病毒-2ul26基因，衣壳蛋白，免疫测定和蛋白酶抑制剂
US5506115A (en) * 1994-04-29 1996-04-09 G. D. Searle & Co. Reagent and method for determining activity of herpes protease
AU2395095A (en) * 1994-04-29 1995-11-29 G.D. Searle & Co. Method of using (h+/k+) atpase inhibitors as antiviral agents
US5486470A (en) * 1994-07-21 1996-01-23 Merck & Co., Inc. Purified herpes simplex virus protease and methods of purification
US5618685A (en) * 1995-04-06 1997-04-08 Merck & Co., Inc. Activation of herpes simplex virus protease by kosmotropes
US5985872A (en) * 1995-05-24 1999-11-16 G.D. Searle & Co. 2-amino-benzoxazinones for the treatment of viral infections
EP0828823A4 (en) * 1995-06-01 1999-02-10 Merck & Co Inc HERPES SIMPLEX TYPE 1 VIRUS PROTEASE MUTANTS AND VECTORS THEREOF
US6083711A (en) * 1996-05-15 2000-07-04 Smithkline Beecham Corporation Proteases compositions capable of binding to said site, and methods of use thereof
US6756207B1 (en) 1997-02-27 2004-06-29 Cellomics, Inc. System for cell-based screening
EP1131471B1 (en) * 1998-10-30 2002-10-02 Cellomics, Inc. A system for cell-based screening
WO2001046448A1 (en) * 1999-12-23 2001-06-28 The Board Of Regents Of The University Of Texas System Inhibition of cellular proteases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3800233A1 (de) * 1988-01-07 1989-07-20 Hans Prof Dr Dr Wolf Methoden fuer die gentechnologische produktion einer rekombinanten, enzymatisch aktiven hiv spezifischen protease und der vorlaeufermolekuele der gruppenspezifischen antigene (gag) und der polymerase (pol) und verwendung dieser produkte in ansaetzen zur testung von hiv-protease spezifischen inhibitoren

Also Published As

Publication number Publication date
FI104427B (fi) 2000-01-31
ATE192494T1 (de) 2000-05-15
EP0514830B1 (en) 2000-05-03
NO922029L (no) 1992-11-25
DE69230984T2 (de) 2000-11-02
NO303645B1 (no) 1998-08-10
HU216622B (hu) 1999-07-28
NO922029D0 (no) 1992-05-22
CA2069460C (en) 2002-12-31
EP0514830A2 (en) 1992-11-25
IE921656A1 (en) 1992-12-02
JP3355202B2 (ja) 2002-12-09
IL101975A (en) 1998-08-16
FI922271A (fi) 1992-11-25
NZ242739A (en) 1994-12-22
EP0514830A3 (en) 1993-06-09
CA2069460A1 (en) 1992-11-25
HU9201723D0 (en) 1992-08-28
DE69230984T4 (de) 2001-04-05
HUT65494A (en) 1994-06-28
AU666305B2 (en) 1996-02-08
DE69230984D1 (de) 2000-06-08
FI922271A0 (fi) 1992-05-19
AU1711292A (en) 1992-11-26
JPH05336964A (ja) 1993-12-21

Similar Documents

Publication Publication Date Title
ES2145742T3 (es) Uso de una proteasa de herpes.
BR7908410A (pt) Meio para deteccao de anticorpos de vhb no soro do sangue,e processo para deteccao da presenca da infeccao por virus da hepatite b em seres humanos
DK217288A (da) Dna, der indkoder t-celleoverfladeproteinet t4, og anvendelse af t4-fragmenter ved behandling af aids
PT83434B (pt) Processo de preparacao de virus recombinantes, de peptidos ou proteinas e de vacinas contra o sindroma de imunodeficiencia adquirida
DE69536039D1 (de) Wirtszelle enthaltend ein rekombinantes Virus, welches ein Antigen exprimiert und ein rekombinantes Virus, welches ein immunstimulatorisches Molekül exprimiert
ATE451462T1 (de) Klonierung und expression von htlv-iii-dns
FI103506B1 (fi) Menetelmä syklisten aminohappojohdannaisten valmistamiseksi ja menetelmässä käytettävä välituote
FI880017A (fi) Menetelmä haiman erittämän trypsiini-inhibiittorivarianttien valmistamiseksi ja menetelmässä käytettävä DNA, vektori ja isäntäsolu
FI945221A (fi) Yhdistelmä-DNA-molekyylejä, jotka koodittavat aminopeptidaasientsyymejä, ja niiden käyttö rokotteiden valmistamiseksi matotartuntoja vastaan
DK0909323T3 (da) Helicobacter pylori-bakterioferritin
DE60228136D1 (de) Cytokin-proteinfamilie
EP0252588A3 (en) Process for the isolation and purification of p. falciparum cs protein expressed in recombinant e. coli, and its use as a vaccine
FI930626A (fi) Proteinstruktur hos vaexttoxingelonin
ATE122055T1 (de) Dna- und rna-moleküle des westlichen subtyps des fsme-virus, polypeptide, die von diesen molekülen codiert werden, und deren verwendung.
DE60027581D1 (de) Design von immunogene
BR0016289A (pt) Vìrus sentinela i do vìrus da hepatite
RU95109909A (ru) Способ ингибирования ретровирусной инфекции, ингибитор протеазы, кодирующая его нуклеиновая кислота и способ рекомбинантного продуцирования серинового ингибитора
WO1998023752A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek
RU94030478A (ru) Рекомбинантный вирус, способ его получения, способ иммунизации, способ получения протеина, вакцинная композиция, применение рекомбинантного вируса
ATE206762T1 (de) Rekombinante viren, enthaltend eine künstliche proteolytische schnittstelle.
Roizman et al. Methods and compositions for the preparation and use of a herpes protease
PT592574E (pt) Processo de producao de proteinas recombinantes e celulas hospedeiras utilizadas
RU93026961A (ru) Способ получения инактивированной гриппозной вакцины
TH63069A (th) โคลนก่อการติดเชื้อ

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 514830

Country of ref document: ES